{"entity":{"id":"nct06639347","kind":"trial","name":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","aka":[],"tldr":"A phase 1/2 trial of SHR-A2102, Adebrelimab and SHR-8068 in bladder & urothelial cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","summary":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma is a phase 1/2 interventional study registered as NCT06639347 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 90 participants planned, started 2024-11-04 and due to reach its primary completion in 2027-05-31. Interventions recorded: SHR-A2102, Adebrelimab injection and SHR-8068 injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06639347","url":"https://clinicaltrials.gov/study/NCT06639347"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-a2102","adebrelimab","shr-8068"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06639347","phase":"1/2","setting":"An Open Label, Multicenter, Phase Ib/Il Study to Evaluate the Safety, Tolerability, and Efficacy of SHR A2102 in Combination With Other Anti-cancer Agents in Patients With Advanced Urothelial Carcinoma","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","enrolled":90,"outcomes":[]},"route":"/trials/nct06639347/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/"},{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}